Diana Turner catches up with Seth Lederman, Co-Founder, CEO and Chairman of Tonix Pharmaceuticals, about the company’s new preventative monoclonal antibody therapy for Lyme disease. DT: For anyone who hasn’t come across the disease before, what is Lyme disease and how is it contracted? SL: Lyme disease is a tick‑borne… Read More
Biopharmaceutical company Tonix Pharmaceuticals has announced the in-licensing of worldwide rights to TNX-4800, a long-acting human monoclonal antibody targeting the prevention of Lyme disease. TNX-4800 targets the outer surface protein of Borrelia burgdorferi, the causative agent of Lyme disease in humans. TNX-4800 is currently being… Read More
Researchers have identified 35 genes associated with long-term Lyme disease that could potentially be used as biomarkers to diagnose patients with the condition. The findings, from the Icahn School of Medicine at Mount Sinai in New York and published in the journal Cell… Read More
Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva. The Vaccine Against Lyme for Outdoor Recreationists (VALOR) trial will investigate the efficacy, safety and immunogenicity of Pfizer and Valneva’s Lyme disease vaccine… Read More
